LOXO

The Loxo Oncology Purchase Eventually Could Help Eli Lilly Stock

By Ian Bezek, InvestorPlace Contributor
Eli Lilly offers a massive premium, paying $8 billion to buy Loxo Oncology. What's in it for Lilly and its shareholders?

LOXO, LLY: Loxo Oncology Stock Soars on $8 Billion Eli Lilly Deal

By William White, InvestorPlace Writer
Loxo Oncology (LOXO) stock was flying high on Monday following news of an $8-billion deal between it and Eli Lilly (LLY).

Best ETFs for 2018: Don’t Sweat This Quarter for the SBIO ETF

By Todd Shriber, InvestorPlace Contributor
On a year-to-date basis, SBIO still looks good, up 14.30%, or 310 basis points better than the Nasdaq Biotechnology Index. Year-to-date, SBIO is also outpacing the equal-weight S&P Biotechnology Select Industry Index.

7 Killer Stock Picks for the Second Half of 2018

By Harriet Lefton, Writer, TipRanks
These seven top stocks all boast substantial support from the Street. But that's not all ... they also have massive upside potential for the next few months, making these stocks a perfect choice to boost your 2018 portfolio performance.

S&P 500, Dow Jones Close Lower Amid Geopolitical Worries

By Anthony Mirhaydari, InvestorPlace Market Strategist
U.S. equities moved lower on Monday amid a terror attack in London and several other concerns muddying up the geopolitical picture.

Loxo Oncology Inc (LOXO) Shares Skyrocket on Successful Cancer Drug Trial

By William White, InvestorPlace Writer
Loxo Oncology (LOXO) shares were in orbit on Monday following three incredibly successful cancer drug trials for Larotrectinib.